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This study examined inositol phosphate and cAMP regulation by TGF-/31, -fl 2 and -/33 in normal and tumour-derived human oral 
keratinocytes. Previous findings indicated that the cell lines expressed TGF-/3 cell surface receptors and had a range of response to 
exogenous TGF-/3 l, -/32 and -/33 from being refractory to the ligand to marked inhibition. Basal levels of inositol phosphates broadly 
reflected the differentiation status of the cells as demonstrated by involucrin expression, but did not correlate with responsiveness to 
TGF-/31, as measured previously by thymidine incorporation. Treatment of cells with bradykinin or serum caused up-regulation of 
inositol phosphate l vels; by contrast, TGF-/3 l, -/32 and -/33 failed to modulate inositol phosphates. In two turnout-derived cell lines, 
the TGF-/3 isoforms had no effect on cAMP levels, despite a significant increase in cAMP using a potent agonist of adenylate cyclase 
(forskolin). Furthermore, the cAMP analogue, dibutyryl cAMP, failed to mimic the inhibitory or refractory responses of TGF-fl in these 
cell lines. The results demonstrate hat in normal and tumour-derived human oral keratinocytes, TGF-/3 signal transduction is not 
mediated by inositol phosphates or cAMP. 
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I. Introduction 
The human TGF-/3 family of growth factors (TGF-fll, 
-/32 and -/33) are highly conserved, ubiquitous peptides 
that exhibit a remarkable diversity of biological action [1]. 
TGF-/3 signal transduction involves serine-threonine ki- 
nase activity on types I and II TGF-fl cell surface recep- 
tors [2,3] and, whilst the nuclear response to TGF-/3 is 
under intense scrutiny at the present ime, very little is 
known about events distal to ligand-receptor interaction 
and, in particular, what second messenger pathways are 
activated by TGF-/3. 
There is some evidence to indicate that TGF-/3 activates 
p21 ras [4] and this, in turn, is thought o lead to mitogen- 
activated protein kinase (MAPK) activation [5]. Ras-inde- 
pendent TGF-fl-mediated responses have also been identi- 
fied [5]. Further, gene expression elicited by TGF-/3 treat- 
ment is sensitive to pertussis toxin, implying a role for 
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G-proteins [6-10], adenylate cyclase [l l] and, possibly, 
phospholipases [ 12,13]. G-protein activation is also closely 
linked to the regulation of cAMP; TGF-/31 counteracts he 
effects of cAMP analogues whilst having no effect on 
ligand-mediated increases in cAMP concentration [14,15]. 
In addition, protein kinase C (PKC) is translocated from 
the cytosol to the cell membrane following treatment of 
cells with TGF-fl 1 [16] but whether this is associated with 
ligand-induced PKC activation via changes in phospho- 
inositide metabolism is currently unknown. 
Studies to examine TGF-/3-induced second messenger 
pathways have used cells of different species, cells of both 
epithelial and fibroblast origin which are inhibited and 
stimulated by TGF-/3, respectively, and genetically- 
manipulated cell lines. There are few data comparing the 
effects of the different TGF-/3 isoforms (-/31, -/32 and 
-/33). We have available a number of human tumour-de- 
rived oral keratinocyte cell lines, together with normal oral 
keratinocytes, in which the response to TGF-/3 isoforms is 
variable and in which types I, II and III TGF-/3 receptors 
are expressed [17]. If specific second messenger pathways 
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are involved in TGF-/3 signal transduction, it might be 
anticipated that these parameters would change in cells 
having a range of response to the ligand. 
The purpose of this study, therefore, was to examine 
inositol phosphate metabolism and cAMP production in 
normal and tumour-derived human oral keratinocytes fol- 
lowing treatment with TGF-/31, -/3 2 and -/3 3. 
2. Materials and methods 
2.1. Cell culture 
Normal human keratinocytes and untreated primary oral 
squamous cell carcinomas were cultured as described pre- 
viously [18]. Briefly, cells were maintained in culture 
media (DMEM/Ham's F12 Nut mix, 1:1; Gibco) supple- 
mented with 10% (v/v)  foetal calf serum (FCS), 0.6 
/zg/ml L-glutamine, 0.5 mg/ml NaHCO 3 and 0.5 /~g/ml 
hydrocortisone at 37°C in 95% air/5% CO 2. Normal 
keratinocytes were cultured in the presence of 3T3 fibrob- 
last support; fibroblasts were selectively removed prior to 
inositol phosphate and cAMP assays. 
Normal and tumour-derived keratinocytes xpress vari- 
able proportions of types I, II and III TGF-/3 cell surface 
receptors, demonstrate a range of response to exogenous 
TGF-/31, from being refractory to the ligand (H314) to 
marked inhibition, and express variable amounts of involu- 
crin (Table 1) [17,19]. 
2.2. [3H]Inositol phosphate assay 
Cells were seeded into 35-mm culture dishes (2 X 105 
cells/dish) and grown for 5-7 days in culture medium 
containing 10% (v/v)  FCS until 70-80% confluent. 24 h 
prior to the assay, cells were labelled with [3H]myo-in- 
ositol (10 /zCi/ml; 17 Ci/mM; Amersham) in inositol- 
free, serum-free culture medium (assay medium; Gibco). 
Following labelling, the cells were washed ( X 2) in DMEM 
and equilibrated at 37°C for 30 min in fresh assay medium 
containing 10 mM LiC1 before the addition of either 
recombinant TGF-/31, TGF-/32, TGF-/33 (1 ng/ml), serum 
(10% v/v)  or bradykinin (10nM). The assay was termi- 
nated after 30 min by the replacement of the assay medium 
with ice-cold perchloric acid (18%, w/v)  and then the 
addition of 100 /~1 EDTA (100 mM, pH 8). Cells were 
fixed on ice for 30 min prior to the addition of 1 ml 
tri-n-octylamine and 1,1,2-trichlorotrifluoroethane 
( l : lv /v) .  The mixture was transferred to capped, 2-ml 
polypropylene tubes and centrifuged at 12000 × g for 2 
min. The aqueous phases were loaded onto a Dowex l-X8 
(formate form) ion exchange column (750 /zl bed volume; 
Biorad) and after washing (5 X 5 ml) with water, the total 
inositol phosphates (IP1, IP2, IP3, IP4) and glycerophos- 
phoinositides (GroPIns) were collected by sequential elu- 
tion with 4 X 2 ml washes of the following solutions; 
(GroPins: 5 mM sodium tetraborate, 60 mM sodium for- 
mate; IPI: 200 mM ammonium formate, 100 mM formic 
acid; IP2:400 mM ammonium formate, 100 mM formic 
acid; IP3:700 mM ammonium formate, 100 mM formic 
acid; IP4:1 M ammonium formate, 100 mM formic acid). 
An equal volume (8 ml) of Quicksafe A scintillant (Zinsser 
Analytic) was added to the fractions which were then 
counted by liquid scintillation [20]. Preliminary studies 
indicated that following a 30-min incubation with serum, 
only IP1 levels were elevated. The IPI-IP4 data therefore, 
were pooled to give total inositol phosphate production 
over a 30-min period. 
2.3. Cyclic AMP production 
Cells were seeded into 35-mm culture dishes (2 X 105 
cells/dish) and grown for 5-7 days in culture medium 
containing 10% (v/v)  FCS until 70-80% confluent. Cul- 
ture media was replaced with 1 ml Biggers BGJ medium 
(Fitton-Jackson modification; Sigma) supplemented with 
NaHCO 3 (0.5 mg/ml) and equilibrated at 37°C for 30 
min. 10 /xl 3-isobutyl-l-methylxanthine (IBMX; 100 mM 
in ethanol) was then added and the dishes left for a further 
5 min. TGF-/31, TGF-/32, TGF-/33 (10 ng/ml; R&D) or 
forskolin (1 /~M; Sigma) was added to the medium and the 
cells incubated at 37°C for 5 min. The reaction was 
terminated by the addition of 1 ml ice-cold acidified 
ethanol (200 mM HC1 in 100% ethanol) and the plates left 
overnight at -20°C. The supernatants were lyophilized 
and the samples tored at -20°C. 
Cyclic AMP production was determined by a competi- 
tive binding assay [21]. Standard concentrations of unla- 
belled cAMP (0.125-16 pmol; Sigma) and lyophilized 
samples were prepared in 50 /xl assay buffer (50 mM 
Tris-HCl, 4 mM EDTA; pH 7.5). 50 ml [3H]cAMP (0.5 
/zCi/ml; Amersham) and 100 /xl diluted cAMP binding 
protein [21] were added to the samples and standards and 
incubated on ice for 2 h. 100 ~1 of charcoal mixture (0.5% 
w/v  BSA; 4% w/v  Norit GSX charcoal) was then added 
and the solutions briefly vortexed. Samples and standards 
were centrifuged at 12000 X g for 2 min. 200-/~1 aliquots 
of supernatant were collected and counted in 4 ml Op- 
tiphase 'Safe' scintillant (LKB) in a/3-scintillation counter. 
2.4. [ ~H]Thymidine incorporation following treatment with 
dibutyryl cAMP 
Assays of [3H]thymidine incorporation following treat- 
ment of cells with mitogens have been reported previously 
[22]; similar techniques were used to examine the effect of 
dibutyryl cAMP. Cells were seeded into 24-well plates 
(5 X 10 4 cells/well) and grown for 5-7 days in culture 
medium containing 10% (v/v)  FCS until 70-80% conflu- 
ent. Culture media was replaced with serum-free culture 
medium (assay medium) with or without the addition of 
dibutyryl cAMP (1 mM). The cells were then incubated for 
24 h prior to assay. 
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2.5. Statistics 
Mean and standard deviation values were compared 
using the two-sample t-test with a probability (P)  of 
< 0.05 taken as being statistically significant. 
3. Results 
3.1. [3H]-labelled inositol phosphate release 
Fig. 1A shows the regulation of total inositol phosphate 
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Fig. 1. [3H]Inositol phosphate production. (A) Normal and tumour-derived human oral keratinocytes were incubated with TGF-/31 (1 ng/ml)  and a 
positive control (10% v /v  serum). (B) H357 was incubated with TGF-fl 1, -/32, -/33 (1 ng/ml)  and a positive control (10 nM bradykinin). [3H]inositol 
phosphate production was expressed per 106 cells; cells were counted in parallel culture dishes. Results are the means and standard eviations of triplicate 
determinations. Statistical correlations were made against he assay medium control. * P < 0.05, * * P < 0.01. 
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Fig. 2. cAMP release in H357 and H376 following treatment with TGF-/31, -/32, -/33 (1 ng/ml)  or forskolin (10 raM). cAMP was expressed per 106 
cells; cells were counted in parallel culture dishes. Results are the means and standard eviations of triplicate determinations. Statistical correlations were 
made against he assay medium control. * P < 0.05, * * P < 0.01. 
cell lines with TGF-/31 or foetal calf serum (10%). There 
was a significant increase in [3H]inositol phosphates after 
incubation with 10% serum (H357, H376 > H103, H157 
> normal, H314 > H400), but there was no significant 
increase in [3H]inositol phosphate production after TGF-/31 
treatment. The baseline turnover of inositol phosphates 
Table 1 
Characteristics of the normal and tumour-derived human oral keratinocyte 
cell lines 
Cell line % Inhibition TGF-/3 Receptor Type 2 lnvolucrin 
to TGF-/31 i I II III expression 3 
Normal 76 32.1 6.9 61.0 + + + 
H103 33 20.3 17.9 61.8 + + 
H157 18 26.0 9.9 64.1 + + 
H314 R 13.0 5.8 81.2 0 
H357 86 25.6 13.9 60.5 + 
H376 90 54.0 2.0 44.0 0 /+ 
H400 88 73.7 16.7 9.6 0 
I The effect of TGF-/31 (0.1 ng/ml  for 24 h) on the normal and 
tumour-derived human oral keratinocyte cell lines has been reported 
previously [17]. H357 was inhibited by TGF-/32 and TGF-/33 by 43% 
and 18%, respectively, whilst H376 was inhibited by TGF-/32 and 
TGF-/33 by 21% and 15%, respectively (unpublished observations). 
Values are expressed as a percentage of control (absence of ligand). R, 
refractory to ligand. 
2 The expression of types I, II and III TGF-fl receptors has been 
examined previously using affinity cross-linking techniques. Autoradio- 
graphs were analysed with an integrated ensitometer and the receptor 
type was expressed as a percentage of the total area of the scanning trace 
on an interactive image analyser [17]. 
3 The expression of involucrin has been examined previously by Western 
blot analysis [19]. 
Marked increased (+ + + ), increased (+ + ), minimal (+)  and absence 
(0) of involucrin expression. 
(H157 > Normal, H103 > H314, H357, H376, H400) 
broadly parallel the expression of involucrin, but not TGF- 
/31-mediated thymidine incorporation (r = - 0.404 ), these 
cell lines (Table 1). 
As with TGF-/31, TGF-/32 and TGF-/33 failed to regu- 
late [3H]inositol phosphate production in H357 (Fig. 1B), 
despite evidence that this pathway was intact following 




















Fig. 3. [3H]Thymidine incorporation following treatment with dibutyryl 
cyclic AMP (1 raM). Results are expressed as a percentage of untreated 
controls and are the means and standard deviations of quadruplicate 
determinations. Statistical correlations were made against the assay 
medium control. * P < 0.05, * * P < 0.01. 
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3.2. cAMP production 
Fig. 2 shows the amount of cAMP produced by two 
tumour-derived human oral keratinocyte cell lines, H357 
and H376, following treatment with TGF-/3 1, TGF-/32 and 
TGF-/33 or forskolin (a potent activator of adenylate cy- 
clase). The TGF-/3 isoforms did not modulate intracellular 
cAMP in either cell line despite the control (forskolin) 
indicating that this pathway was intact. 
Fig. 3 shows the effect of dibutyryl cAMP on thymidine 
incorporation i  tumour-derived keratinocyte cell lines in 
the absence of TGF-/3. The cAMP analogue inhibited 
(H103, H157, H314) or had no effect (H376, H400) on 
thymidine incorporation i these cell lines. 
4. Discussion 
Recent data indicate that murine keratinocyte differenti- 
ation is associated with an increase in intracellular calcium 
and stimulation of inositol phospholipid metabolism [23]. 
The results of the present study support these findings 
because baseline levels of inositol phosphates broadly 
correlated with the amount of involucrin, a marker of 
terminal keratinocyte differentiation, previously demon- 
strated in extracts of the cell lines (Table 1) [19]. Normal 
keratinocytes, H103 and H157 contained the highest level 
of involucrin, whilst H314, H357, H376 and H400 ex- 
pressed considerably lower levels, results that reflect the 
degree of tumour cell differentiation a d which parallel the 
distribution of basal inositol phosphates in the present 
study. This generalization, however, should be treated with 
caution because it might have been expected that normal 
keratinocytes, which express the most involucrin, would 
also have the highest unstimulated levels of total inositol 
phosphates. In fact, H157 produced the greatest levels of 
unstimulated inositol phosphates in this study. 
Signal transducing systems associated with TGF-/3 have 
largely remained an enigma. In the present study, there 
was no relationship between the basal levels of total 
inositol phosphates and the previously reported growth 
inhibitory response to TGF-/31 in these cell lines [17]. In 
addition, TGF-/3 isoforms did not change the levels of 
inositol phosphates in both normal and tumour-derived 
human oral keratinocytes. Our results reflected an acute 
response to TGF-/3. Others [12,13] have observed changes 
in inositol phosphates in response to TGF-/3 over longer 
periods of time which may result from non-specific 
changes. The results of the present study support previous 
observations in TGF-/3 inhibited Chinese hamster lung 
fibroblasts [24], but contrast o findings in TGF-/3 stimu- 
lated rat-1 cells [12]. Recent data indicates that TGF-/31 
growth inhibition is mediated by cyclin-dependent kinases 
and their inhibitors [25]. Furthermore, there is an increas- 
ing volume of evidence to show that the control of cellular 
proliferation and extracellular matrix elaboration by TGF- 
/31 occur by distinct signal transduction pathways [26]. 
The results of the present study suggest hat neither the 
inhibition of cell growth or the elaboration of extracellular 
matrices by TGF-/31 are mediated by changes in inositol 
phosphate metabolism in human keratinocytes. This sug- 
gests that the correlation between basal levels of inositol 
phosphates and involucrin expression, observed in this 
study, is independent of TGF-/31. Further, the results of 
the present study demonstrated no obvious differences 
between ormal and tumour-derived cells, suggesting that 
the inositol phosphate signal transduction pathways are not 
compromised by tumour-development. 
There is increasing evidence that TGF-/3 signal trans- 
duction is mediated through G-proteins [6-10] and one 
component of the prototypic G-protein signal transduction 
pathway is cAMP. The results of the present study, how- 
ever, indicated that TGF-/31, -/32 and -/33 did not modu- 
late cAMP levels in two tumour-derived human oral kera- 
tinocyte cell lines. Similar observations have been reported 
previously in rat fibroblasts and human thyroid epithelial 
cells [14,15]. Further confirmation that cAMP is not in- 
volved in TGF-/3 signal transduction i keratinocytes i  
demonstrated by the cAMP analogue studies. Dibutyryl 
cAMP, for example, inhibited (H103, H157) or had no 
effect (H376, H400) on thymidine incorporation i TGF- 
/3-responsive cell lines. In addition, thymidine incorpora- 
tion was down-regulated by dibutyryl cAMP in a TGF-fl 
unresponsive c ll line (H314). Vivien et al. [27], however, 
demonstrated that a TGF-/3-induced G2/M delay in rabbit 
articular chondrocytes was associated with a decrease in 
cAMP, whilst Anderson et al. [11] showed that TGF-/31 
stimulated adenylate cyclase activity and the cAMP re- 
sponse element binding protein (CREB) in renal epithelial 
cells. When the inositol phosphate and cAMP data are 
taken together, the results emphasize the importance of 
defining cell origin, together with the nature of the mito- 
genic response to TGF-fl, before interpreting ligand in- 
duced second messenger systems. 
Adenylate cyclase activity is tightly regulated by in- 
hibitory (Gi) and stimulatory (Gs) guanine nucleotide bind- 
ing proteins. Lack of cAMP elevation in response to 
TGF-/3 suggests Gs is unlikely to be activated but a role 
for Gi cannot be excluded. Indeed, receptors which couple 
to Gi are known to mediate ras-activation and subsequent 
signalling via MAP kinase [28]. It is currently perceived 
that both these factors are involved in TGF-/3 signal 
transduction [4,5]. Studies are currently underway to exam- 
ine the role of Gs and Gi in TGF-/3 signal transduction i
our keratinocyte c ll lines. 
In conclusion, the results of this study indicate that 
TGF-/3 signal transduction is not mediated by either inosi- 
tol phosphates or cAMP in normal and tumour-derived 
human oral keratinocytes. The diverse biological effects of 
TGF-/3, therefore, are likely to be mediated by multiple 
signal transduction pathways. 
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